A dual role of miR-22 modulated by RelA/p65 in resensitizing fulvestrant-resistant breast cancer cells to fulvestrant by targeting FOXP1 and HDAC4 and constitutive acetylation of p53 at Lys382

MTA1-activated Epi-microRNA-22 regulates E-cadherin and prostate cancer invasiveness

(2017) Swati Dhar et al.   FEBS LETTERS

Targeting NF-κB RelA/p65 phosphorylation overcomes RITA resistance

(2016) Yiwen Bu et al.   CANCER LETTERS

FOXP1 enhances tumor cell migration by repression of NFAT1 transcriptional activity in MDA-MB-231 cells

(2016) Sevil Oskay Halacli   CELL BIOLOGY INTERNATIONAL

Ibrutinib downregulates a subset of miRNA leading to upregulation of tumor suppressors and inhibition of cell proliferation in chronic lymphocytic leukemia

(2016) L M Saleh et al.   LEUKEMIA

miR-22 and miR-29a Are Members of the Androgen Receptor Cistrome Modulating LAMC1 and Mcl-1 in Prostate Cancer

(2015) Lorenza Pasqualini et al.   MOLECULAR ENDOCRINOLOGY

The microRNA miR-22 inhibits the histone deacetylase HDAC4 to promote TH17 cell–dependent emphysema

(2015) Wen Lu et al.   NATURE IMMUNOLOGY

Altered radiation responses of breast cancer cells resistant to hormonal therapy

(2015) Lidiya Luzhna et al.   Oncotarget

A Regulatory Loop Involving miR-22, Sp1, and c-Myc Modulates CD147 Expression in Breast Cancer Invasion and Metastasis

(2014) L.-M. Kong et al.   CANCER RESEARCH

miR-22 regulates expression of oncogenic neuro-epithelial transforming gene 1, NET1

(2014) Hafiz M. Ahmad et al.   FEBS Journal

MicroRNA-Antagonism Regulates Breast Cancer Stemness and Metastasis via TET-Family-Dependent Chromatin Remodeling

(2013) Su Jung Song et al.   CELL

The Oncogenic MicroRNA miR-22 Targets the TET2 Tumor Suppressor to Promote Hematopoietic Stem Cell Self-Renewal and Transformation

(2013) Su Jung Song et al.   Cell Stem Cell

NFκB signaling is important for growth of antiestrogen resistant breast cancer cells

(2012) Christina W. Yde et al.   BREAST CANCER RESEARCH AND TREATMENT

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

(2012) Christina Davies et al.   LANCET

Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen receptor-positive breast cancer patients. Very late results of the ‘gruppo di ricerca per la chemio-ormonoterapia adiuvante (GROCTA)’ 01-Trial in early breast cancer

(2011) Francesco Boccardo et al.   BREAST CANCER RESEARCH AND TREATMENT

Targeting NFĸB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2

(2011) James W. Antoon et al.   CANCER BIOLOGY & THERAPY

Tumor Suppressor miR-22 Determines p53-Dependent Cellular Fate through Post-transcriptional Regulation of p21

(2011) N. Tsuchiya et al.   CANCER RESEARCH

Overexpression of miR-22 reverses paclitaxel-induced chemoresistance through activation of PTEN signaling in p53-mutated colon cancer cells

(2011) Jian Li et al.   MOLECULAR AND CELLULAR BIOCHEMISTRY

FOXP1, an Estrogen-Inducible Transcription Factor, Modulates Cell Proliferation in Breast Cancer Cells and 5-Year Recurrence-Free Survival of Patients with Tamoxifen-Treated Breast Cancer

(2011) Takashi Shigekawa et al.   Hormones & Cancer

Benefits of early and prolonged fulvestrant treatment in 848 postmenopausal advanced breast cancer patients

(2010) Mathias Warm et al.   BREAST CANCER RESEARCH AND TREATMENT

microRNA-22, downregulated in hepatocellular carcinoma and correlated with prognosis, suppresses cell proliferation and tumourigenicity

(2010) J Zhang et al.   BRITISH JOURNAL OF CANCER

An estrogen receptor α suppressor, microRNA-22, is downregulated in estrogen receptor α-positive human breast cancer cell lines and clinical samples

(2010) Jianhua Xiong et al.   FEBS Journal

MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways

(2010) X Rao et al.   ONCOGENE

MicroRNAs: Target Recognition and Regulatory Functions

(2009) David P. Bartel   CELL

Her2 activates NF-κB and induces invasion through the canonical pathway involving IKKα

(2009) E C Merkhofer et al.   ONCOGENE

CDK Inhibitors: Cell Cycle Regulators and Beyond

(2008) Arnaud Besson et al.   DEVELOPMENTAL CELL

Cooperative regulation in development by SMRT and FOXP1

(2008) K. Jepsen et al.   GENES & DEVELOPMENT

Most mammalian mRNAs are conserved targets of microRNAs

(2008) R. C. Friedman et al.   GENOME RESEARCH

MicroRNA-221/222 Confers Tamoxifen Resistance in Breast Cancer by Targeting p27Kip1

(2008) Tyler E. Miller et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Advances in microRNAs: implications for immunity and inflammatory diseases

(2008) E. Sonkoly et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

HDAC4 Promotes Growth of Colon Cancer Cells via Repression of p21

(2008) Andrew J. Wilson et al.   MOLECULAR BIOLOGY OF THE CELL

Specific Activity of Class II Histone Deacetylases in Human Breast Cancer Cells

(2008) V. Duong et al.   MOLECULAR CANCER RESEARCH

Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?

(2008) Witold Filipowicz et al.   NATURE REVIEWS GENETICS

HDAC4 represses p21WAF1/Cip1 expression in human cancer cells through a Sp1-dependent, p53-independent mechanism

(2008) D Mottet et al.   ONCOGENE